The core management team that hit a home run with the first vascular endothelial growth factor (VEGF) inhibitor for the eye, which resulted in a $900 million merger and acquisition deal, is taking another swing at bringing new molecular entities to the marketplace with a newly formed company. (BioWorld Today)